Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Operating Income (2016 - 2025)

Historic Operating Income for Sunshine Biopharma (SBFM) over the last 13 years, with Q3 2025 value amounting to -$1.1 million.

  • Sunshine Biopharma's Operating Income rose 178.42% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.5 million, marking a year-over-year decrease of 3180.3%. This contributed to the annual value of -$5.8 million for FY2024, which is 2145.78% down from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Operating Income is -$1.1 million, which was up 178.42% from -$2.1 million recorded in Q2 2025.
  • Sunshine Biopharma's Operating Income's 5-year high stood at -$279631.0 during Q4 2021, with a 5-year trough of -$23.4 million in Q4 2022.
  • Moreover, its 5-year median value for Operating Income was -$1.2 million (2022), whereas its average is -$2.3 million.
  • Its Operating Income has fluctuated over the past 5 years, first plummeted by 825515.73% in 2022, then surged by 9491.85% in 2023.
  • Quarter analysis of 5 years shows Sunshine Biopharma's Operating Income stood at -$279631.0 in 2021, then tumbled by 8255.16% to -$23.4 million in 2022, then skyrocketed by 94.92% to -$1.2 million in 2023, then tumbled by 71.64% to -$2.0 million in 2024, then skyrocketed by 46.68% to -$1.1 million in 2025.
  • Its Operating Income stands at -$1.1 million for Q3 2025, versus -$2.1 million for Q2 2025 and -$1.3 million for Q1 2025.